NCOA5 Haploinsufficiency Results in Glucose Intolerance and Subsequent Hepatocellular Carcinoma  by Gao, Shenglan et al.
Cancer Cell
ArticleNCOA5 Haploinsufficiency Results in Glucose
IntoleranceandSubsequentHepatocellularCarcinoma
Shenglan Gao,1,2 Aimin Li,1,4 Feiye Liu,4 Fengsheng Chen,1,4 Mark Williams,1,3 Chengliang Zhang,1 Zakiya Kelley,1
Chin-Lee Wu,5 Rongcheng Luo,4,* and Hua Xiao1,*
1Department of Physiology, Michigan State University, East Lansing, MI 48824, USA
2Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI 48824, USA
3Cell and Molecular Biology Program, Michigan State University, East Lansing, MI 48824, USA
4Cancer Center, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China
5Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
*Correspondence: luorc01@163.com (R.L.), xiaoh@msu.edu (H.X.)
http://dx.doi.org/10.1016/j.ccr.2013.11.005SUMMARYType 2 diabetes (T2D) and male gender are associated with hepatocellular carcinoma (HCC) development.
We demonstrate that heterozygous deletion of the Ncoa5 gene causes spontaneous development of HCC
exclusively in male mice. Tumor development is preceded by increased interleukin-6 (IL-6) expression,
early-onset glucose intolerance, and progressive steatosis and dysplasia in livers. Blockading IL-6 over-
expression averts glucose intolerance and partially deters HCC development. Moreover, reduced NCOA5
expression is associated with a fraction of human HCCs and HCCs with comorbid T2D. These findings
suggest that NCOA5 is a haploinsufficient tumor suppressor and that NCOA5 deficiency increases suscep-
tibility to both glucose intolerance and HCC, partially by increasing IL-6 expression. Thus, our findings open
additional avenues for developing therapeutic approaches to combat these diseases.INTRODUCTION
Hepatocellular carcinoma (HCC) is the fifth most common and
the thirdmost lethal cancer worldwide, with increasing incidence
in many developed countries, including the United States (El-
Serag and Mason, 1999; El-Serag and Rudolph, 2007). The inci-
dence of HCC is two to four times higher in men than in women.
The risk factors for HCC include hepatitis B and C viral infection,
aflatoxin-B exposure, alcohol consumption, inborn metabolic
diseases, and diabetes (Coleman, 2003; Coughlin et al., 2004;
Donadon et al., 2008; Staib et al., 2003). While hepatitis viral
infection currently remains themajor risk factor for HCC globally,
diabetes is the secondmost common risk factor for HCC (36%of
HCC cases) in the United States, topped only by nonalcoholic
fatty liver disease (59% of HCC cases between 2002 and 2008)
(Sanyal et al., 2010). Furthermore, the incidence of HCC in
diabetic patients increases with male gender and duration of
diabetes (El-Serag et al., 2009; El-Serag and Mason, 1999; LaiSignificance
The association between T2D and HCC is of great public health
risks for many cancers, but also due to increasing global T2
NCOA5 haploinsufficiency activates a pathogenic pathway
HCC development in mice. Reduced NCOA5 expression is ob
with comorbid T2D. These results reveal NCOA5 haploinsuffi
ourNcoa5+/mouse model of glucose intolerance with comorb
ular basis and therapeutic responsiveness of HCC with comor
Caet al., 2012; McGlynn and London, 2011). With growing global
prevalence of diabetes and declining prevalence of hepatitis
virus B and C infections, type 2 diabetes (T2D) may become an
even more important risk factor for HCC in the future (McGlynn
and London, 2011). However, the molecular mechanisms under-
lying the association between these two diseases are largely
unknown (Donadon et al., 2008; Feng, 2012).
Inflammation is known as a common pathogenic condition
leading to both T2D and HCC (Donath and Shoelson, 2011; Gio-
vannucci et al., 2010; Kalra et al., 2008; Olefsky andGlass, 2010).
Of particular interest is the implication of inflammatory cytokine
interleukin-6 (IL-6) in the pathogenesis of these two diseases.
Even though the role of IL-6 in insulin resistance has been
debated, the available evidence has clearly indicated that the
effect of increased IL-6 expression on insulin action is highly
tissue specific and dependent on physiological state (Kim
et al., 2009). It is generally accepted that IL-6 released from skel-
etal muscle during exercise can improve insulin sensitivityconcern, not only because T2D is associated with elevated
D prevalence and limited therapies for HCC. We show that
concomitantly leading to impaired glucose tolerance and
served in a substantial fraction of human HCCs and HCCs
ciency as a genetic link between T2D and HCC. Moreover,
id HCC provides a valuable platform for studying the molec-
bid T2D.
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Decreased NCOA5 Causes Glucose Intolerance and HCC(Ellingsgaard et al., 2011) and global deletion of the Il-6 gene
promotes insulin resistance in mice (Matthews et al., 2010). On
the other hand, increased IL-6 expression in the liver, induced
by chronic inflammation, can promote hepatic insulin resistance
and HCC (Fernandez-Real et al., 2001; Johnson et al., 2012;
Klover et al., 2003, 2005; Liu et al., 2007; Pang et al., 2011).
Consistent with this, inhibition of elevated IL-6 signaling
increases insulin sensitivity in mice and humans with diabetes
and/or rheumatoid disease (Klover et al., 2003, 2005; Ogata
et al., 2011; Schultz et al., 2010). Moreover, studies on obesity
or diethylnitrosamine (DEN)-induced mouse models of HCC
demonstrated that IL-6 production from macrophages, in liver
and adipose tissues, is necessary for HCC development in
male mice (Naugler et al., 2007; Park et al., 2010). Importantly,
it was recently reported that aberrant activation of the IL-6-
STAT3 signaling pathway is a characteristic of HCC develop-
ment in mice and humans (Bard-Chapeau et al., 2011).
Therefore, unraveling the regulation of IL-6 expression in T2D
and HCC would be important for the understanding of mecha-
nisms underlying the association between the two diseases.
Estrogen signaling is another regulatory pathway that plays
important roles in the pathogenesis of both T2D and HCC
(Naugler et al., 2007; Tiano et al., 2011). It is well documented
that estrogen and estrogen receptor a (ERa) can regulate in-
flammatory cytokine expression, glucose and lipid homeostasis,
and pancreatic b cell survival (Nadal et al., 2009), thereby
providing protection from T2D and HCC development. ERa
modulates transcription of genes through interaction with
coactivators and corepressors as well as other transcription
factors. The nuclear receptor coactivator 5 (NCOA5), also called
coactivator independent of AF2 (CIA), is a unique coactivator
that contains both coactivator and corepressor domains and is
known to modulate ERa-mediated transcription (Jiang et al.,
2004; Sauve´ et al., 2001). Recent linkage analysis revealed that
NCOA5, along with two nearby genes in the 20q13.1 region, is
associated with T2D, implying NCOA5 as a possible T2D
susceptibility gene (Bento et al., 2008; Lewis et al., 2010). In
the present study, we investigate the role of NCOA5 in the devel-
opment of T2D and HCC.
RESULTS
NCOA5 Haploinsufficiency Results in Late-Onset HCC
Exclusively in Male Mice
To assess the role of NCOA5 in mouse development and
tumorigenesis, we generated genetically engineered Ncoa5+/
mice (Figures S1A and S1B available online). Ncoa5 expression
was detected in all mouse tissues examined, but with variable
levels that were lowest in liver (Sauve´ et al., 2001). Ncoa5+/
mice were found to have a 50% decrease in NCOA5 expres-
sion within the liver (Figures S1C and S1D). Ncoa5+/ mice
appeared indistinguishable from their wild-type littermates at
the age of 8 weeks and had a body weight and liver to body
weight ratio similar to the Ncoa5+/+ male mice (Figures S1E
and S1F) at ages 2, 6, and 10 months. However, Ncoa5+/
male mice suffered from a severe fertility defect, whereas
Ncoa5+/ female mice were fertile (S.G., F.C., G. Perez, and
H.X., unpublished data). Consequently, Ncoa5/ homozygous
embryos and mice were not generated. We monitored a cohort726 Cancer Cell 24, 725–737, December 9, 2013 ª2013 Elsevier Inc.of wild-type and Ncoa5+/ mice for tumor development for
18 months. Mice were euthanized and subjected to complete
necroscopy when they were moribund or reached 18 months
of age. We observed that 94% of Ncoa5+/ male mice spon-
taneously developed tumors in the liver at 10–18 months of
age, whereas Ncoa5+/ female and Ncoa5+/+ male mice did
not (Figures 1A–1C). In a cohort of wild-type and Ncoa5+/
mice of Balb/c genetic background, a liver tumor incidence of
71%was observed in Ncoa5+/males (Figure S1G). Histological
analysis revealed that tumors were well to moderately differ-
entiated HCCs, often with a more than two-cell-thick trabecular
(Figures 1D–1F) or pseudoglandular pattern (Figure 1G), occa-
sionally with lung metastasis (Figures 1H and 1I) and necrosis
(Figure 1J). Tumor cells had morphological resemblance to
hepatocytes; however, they displayed nuclear pleomorphism,
some with prominent nucleoli and vacuolation (Figures 1F and
1K). Some of the tumor cells were a-fetal protein (AFP) or
Ep-CAM positive (Figure S1H). NCOA5 expression was detect-
able using western blot analysis (Figure S1I) and RT-PCR, and
no mutations were found in Ncoa5 cDNAs of two tumors that
were examined (data not shown). These results suggest that
NCOA5 is haploinsufficient to suppress HCC development in
male mice.
NCOA5 Haploinsufficiency Results in Early-Onset
Glucose Intolerance in Male Mice
Given the finding that the human NCOA5 gene is a possible
T2D susceptibility gene (Bento et al., 2008; Lewis et al., 2010),
blood glucose tests, glucose tolerance tests (GTTs), and insulin
tolerance tests (ITTs) were performed in 6-week-old Ncoa5+/+
and Ncoa5+/ mice. Six-week-old Ncoa5+/ male mice showed
significantly elevated levels of fasting blood glucose as well as
markedly decreased glucose tolerance and insulin sensitivity
compared to Ncoa5+/+ littermates (Figures 2A–2C). Similar
results were obtained in Ncoa5+/ mice in a Balb/c genetic
background (Figures S2A–S2C). Elevated fasting blood glucose
levels and glucose intolerance were continuously present in
Ncoa5+/ male mice at the age of 20 weeks (Figures S2D–
S2F). Interestingly, these differences were not observed
between Ncoa5+/ and Ncoa5+/+ female mice (Figure 2D).
Consistent with impaired insulin signaling, insulin-stimulated
phosphorylation of IR-b, IRS-1, and AKT was reduced in livers
of Ncoa5+/ male mice, whereas total IR-b, IRS-1, and AKT
protein levels were not affected (Figure 2E). These results
indicate the impairment of insulin signaling in Ncoa5+/ mouse
livers. Surprisingly, no statistically significant difference in
serum insulin levels, in the fasting state and following an intra-
peritoneal glucose load, was detected between these two
groups of mice (Figure 2F). This suggests a partial failure of
functional b cell compensation in Ncoa5+/ male mice. Consis-
tently, there was no significant difference in pancreas size
between Ncoa5+/ and Ncoa5+/+ male mice; the mass and
number of islets were not expanded but rather significantly
reduced in both 8- and 24-week-oldNcoa5+/malemice relative
to Ncoa5+/+ male littermate controls (Figures 2G–2I). Thus,
NCOA5 haploinsufficiency results in the onset of glucose
intolerance in male mice at the age of 6 weeks through inhibition
of both hepatic insulin signaling and pancreatic b cell
compensation.
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A Figure 1. Spontaneous HCC Development in
Ncoa5+/– Male Mice
(A) Kaplan-Meier curves showing tumor-free sur-
vival of wild-type (WT) and Ncoa5+/ mice. Results
are expressed as percentage of mice free of liver
tumors (n = 16–19; p < 0.0001; log-rank test). The
bar graph shows liver tumor incidence of male and
female WT and Ncoa5+/ mice (**p% 0.01).
(B and C) Representative macroscopic appearance
of livers and hematoxylin and eosin (H&E)-stained
liver sections derived from 18-month-old WT and
Ncoa5+/male (B) and female (C) mice. Blue arrows
indicate tumors. Arrowheads indicate the edges of
tumors.
(D–F) H&E-stained HCCs in Ncoa5+/ male mice
showed thicker trabeculae and steatosis at lower
magnification (D and E) and higher magnification (F).
(G) H&E-stained Ncoa5+/ HCC with a pseudo-
glandular pattern.
(H and I) A well-differentiated HCC metastasized
to lung in Ncoa5+/ mice at lower (H) and higher
magnification (I). The blue arrow indicates the met-
astatic tumor.
(J) H&E-stained Ncoa5+/ HCC with necrosis. The
blue arrow indicates a necrotic area.
(K) H&E-stained Ncoa5+/ HCCwith macrovesicular
steatosis.
Scale bars represent 50 mm. See also Figure S1.
Cancer Cell
Decreased NCOA5 Causes Glucose Intolerance and HCCNcoa5+/– Male Mice Developed Apparent Hepatic
Inflammation, Steatosis, and Dysplasia after the Onset
of Glucose Intolerance and prior to the Formation
of HCC
To investigate the effects of NCOA5 on preneoplastic lesion
development, we carried out histological comparisons between
the livers from Ncoa5+/+ and Ncoa5+/ littermates at various
ages. We found that the hepatocellular architecture of 2-month-
old Ncoa5+/ mice is comparable to wild-type littermates. The
livers of Ncoa5+/ male mice at the ages of 6 or 10 months, but
not the livers of age-matched Ncoa5+/+ male (Figure 3A) and
Ncoa5+/ female mice (data not shown), displayed characteristic
features of hepatic dysplasia and steatosis such as architectural
disorganization, cytological atypia, enlarged nucleus, vacuolated
hepatocytes, and increased lipid deposition as revealed byoil red
O staining (Figure 3A). Consistent with these notions, hepatic
triglyceride levels were elevated in Ncoa5+/ male mice
compared to Ncoa5+/+ male mice, whereas serum triglyceride
and free fatty acid levels were comparable in the two groups (Fig-
uresS3A–S3C). In addition,Ncoa5+/, but not thewild-type,male
mice exhibited signs of chronic hepatic inflammation including
immune cell infiltrations around the bile ducts and in the portal
areas as well as focal aggregates of lymphocytes, neutrophils,Cancer Cell 24, 725–737and macrophages (Figure 3B). Masson’s
trichrome staining showed fibrosis with
connective tissue fibers in the periportal
and periductular areas in livers of 10-
month-oldNcoa5+/malemice (Figure 3B).
In parallel with thesemorphologic changes,
serum levels of alanine aminotransferase
(ALT) and AFP were significantly increased
in 6- and 12-month-old Ncoa5+/ male
mice compared to age-matched wild-type males, but not in
2-month-oldmice (Figures 3C and 3D).Moreover, TUNEL assays
detectedmore cell death in the livers ofNcoa5+/malemice (Fig-
ure 3E), while PCNA staining revealed more proliferation in the
livers and liver tumors of Ncoa5+/male mice (Figure 3F). These
results suggest that NCOA5 haploinsufficiency causes develop-
ment of hepatic inflammation, steatosis, and dysplasia prior to
HCC development in male mice.
NCOA5 Deficiency Increased the Transcription of Il-6 by
Enhancing RNA Polymerase II Assembly on the Il-6
Promoter
Proinflammatory cytokines play important roles in hepatic
inflammation and preneoplastic lesions (He and Karin, 2011;
Johnson et al., 2012). We therefore examined the expression
of inflammatory cytokines IL-6 and tumor necrosis factor a
(TNF-a) in Ncoa5+/ and Ncoa5+/+ mice. The mRNA levels of II-
6 and Tnfa in the livers were significantly increased in Ncoa5+/
male mice at the age of 8 and 24 weeks compared to wild-
type controls (Figures 4B and S4A), whereas the serum IL-6
levels were not significantly changed (Figure 4A), indicating
that NCOA5 exerts its regulation of Il-6 expression in the liver
but does not affect the serum level of IL-6. We next asked which, December 9, 2013 ª2013 Elsevier Inc. 727
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Figure 2. Glucose Sensitivity in Ncoa5+/–
Male Mice at the Age of 6 Weeks
(A) Blood glucose levels of fasted 6-week-old and
20-week-old male mice with the indicated geno-
types (n = 7).
(B) GTT of 6-week-old male mice with the indi-
cated genotypes (n = 3). Blood glucose levels were
determined at the indicated times.
(C) ITT of 6-week-old male mice with the indicated
genotypes (n = 4). Blood glucose levels of male
mice with the indicated genotypes at the indicated
times. Note: similar changes in blood glucose
levels and GTT were observed in Ncoa5+/ male
mice in a Balb/c genetic background (Figures
S2B–S2D).
(D) GTT of 6-week-old female mice with the indi-
cated genotypes (n = 4; p > 0.05).
(E) Western blot analysis of liver extracts from WT
and Ncoa5+/ male mice at 6 months of age after
portal vein injection of insulin using antibodies for
pIRb (Tyr 1150/1151), IRb, pAKT (Ser 473) and
AKT. For pIRS1, lysates were immunoprecipitated
with anti-IRS1 antibody and then immunoblotted
with anti-phosphotyrosine antibody. Results
represent two independent experiments with
different pairs of littermates.
(F) Serum insulin concentrations were determined
at the indicated times after glucose challenge (p >
0.05).
(G) Representative H&E staining of pancreases
from 6-month-old WT and Ncoa5+/ male mice
(upper panel). Representative IHC staining of in-
sulin of pancreases from 6-month-old WT and
Ncoa5+/ male mice at lower magnification (mid-
dle panel) and highermagnification (bottom panel).
(H and I) Quantification of the proportion of islet
mass to the pancreas area and the numbers of
islets counted from ten sections of each mouse
from 8-week-old (H) and 24-week-old (I) WT and
Ncoa5+/ male mice. Results are shown in pro-
portion to the pancreas (%; n = 3–4).
All values are mean ± SEM. *p% 0.05; **p% 0.01.
See also Figure S2.
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Decreased NCOA5 Causes Glucose Intolerance and HCCcells displayed higher expression of IL-6 and TNF-a in the liver.
As shown by immunohistochemical (IHC) staining of IL-6 in liver
sections, IL-6 was positively stained in nonparenchymal cells in
livers (Figure 4C). The number of positively stained IL-6 cells is
significantly increased in Ncoa5+/ male livers compared to
Ncoa5+/+ male livers (Figure 4D). In addition, dual immunofluo-
rescent (IF) staining of liver macrophage (Kupffer cells) by
MAC2 and IL-6 or TNF-a antibodies showed a significant in-
crease in numbers of dual IL-6/MAC2-positive and TNF-a/
MAC2-positive macrophages in Ncoa5+/ male mouse livers at
the age of 10 months compared with age-matched Ncoa5+/+
male mouse livers (Figures 4E, 4F, and S4B). These results indi-728 Cancer Cell 24, 725–737, December 9, 2013 ª2013 Elsevier Inc.cate increased activation of Kupffer cells
by NCOA5 haploinsufficiency. Strikingly,
IL-6 and TNF-a expression in hepato-
cytes was not apparently changed in
Ncoa5+/ male mice (Figures 4C and
S4B). In agreement with the effects of
IL-6 on STAT3 and its canonical targetSOCS3 (Senn et al., 2003; Yu et al., 2007), phospho-STAT3
(Tyr705) protein levels and Socs3mRNA levels were significantly
increased in livers ofNcoa5+/malemice comparedwith livers of
wild-typemalemice (Figures 4G and 4H). Increased pSTAT3was
more pronounced in tumors compared with their adjacent
tissues, as the total protein levels of STAT3 were also markedly
increased in tumors (Figure 4G). Moreover, we also demon-
strated that knockdown of NCOA5 resulted in an increased
IL-6 expression in human monocyte/macrophage THP1 cells
(Figures S4C and S4D). These results suggest that NCOA5 hap-
loinsufficiency enhances expression of IL-6 and TNF-a in Kupffer
cells, which in turn activates STAT3-SOCS3 signaling.
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Figure 3. Hepatic Histology and Markers of
Liver Function in Ncoa5+/– Male Mice
Compared to WT Male Mice
(A) Representative H&E-stained liver sections from
male mice with the indicated genotypes and ages.
Arrows indicate vacuolated or enlarged hepato-
cytes. A representative oil red O-stained section
shows severe accumulation of lipids in the liver of
Ncoa5+/male mice at the age of 10 months (bars
represent 50 mm).
(B) Representative H&E-stained liver sections from
male mice showing infiltration of inflammatory
cells in livers of Ncoa5+/ mice. Representative
immunostaining of MAC2 and trichrome staining
of livers from male mice with the indicated geno-
types (bars represent 50 mm).
(C) Serum levels of ALT of male mice with the
indicated ages and genotypes (n = 4–8; *p% 0.05;
N.S., no significance). Values are mean ± SEM.
(D) Serum levels of AFP of male mice with the
indicated ages and genotypes (n = 4–5; *p% 0.05;
**p % 0.01; N.S., no significance). Values are
mean ± SEM.
(E) The bar graph shows mean ± SEM of TUNEL-
positive cells in the liver sections of 18-month-old
WT and Ncoa5+/ male mice (n = 3; *p% 0.05).
(F) The bar graph shows mean ± SEM of PCNA-
positive cells in the liver sections of 18-month-old
WT and Ncoa5+/male mice and liver tumors from
Ncoa5+/ male mice (n = 3; *p% 0.05).
See also Figure S3.
Cancer Cell
Decreased NCOA5 Causes Glucose Intolerance and HCCLigand-bound ERa represses NF-kB-mediated transcriptional
activation of the IL-6 gene in macrophages through direct inter-
action with NF-kB, which binds to the IL-6 promoter responsive
elements (Libermann and Baltimore, 1990; Naugler et al., 2007;
Ray et al., 1994; Stein and Yang, 1995). Since NCOA5 is a coac-
tivator for ERa, we performed quantitative chromatin immuno-
precipitation (qChIP) and luciferase reporter assays to examine
the molecular mechanism by which NCOA5 regulates Il-6
expression. qChIP analysis of a cultured mouse macrophage
cell line, RAW264.7, indicated that NCOA5 assembly on theCancer Cell 24, 725–737,Il-6 promoter (Figure 4I) was increased
upon estrogen stimulation, suggesting
that NCOA5, along with ERa, is recruited
to the Il-6 promoter. In contrast, the
assembly of coactivator CREB-binding
protein (CBP) on the promoter was not
enhanced after estrogen treatment.
Moreover, luciferase reporter assays of
the mouse Il-6 promoter revealed that
NCOA5 could repress lipopolysaccharide
(LPS)-induced Il-6 transcription (Fig-
ure 4J). Consistent with the inhibitory
effect of NCOA5 on Il-6 transcription,
mouse liver tissue qChIP analysis re-
vealed that recruitment of RNA polymer-
ase II (Pol II) and the phosphorylated
form of Pol II on the Il-6 promoter was
significantly increased in Ncoa5+/ livers
when compared withNcoa5+/+ livers (Fig-ure 4K), whereas the assembly of ERa on the promoter was not
changed in Ncoa5+/ livers. These data indicate that NCOA5
acts as a negative coregulator of Il-6 transcription in vivo and
NCOA5 haploinsufficiency increases IL-6 expression through
enhancing recruitment of RNA Pol II to the Il-6 promoter.
NCOA5 Deficiency Increases AR Expression in the
Livers of Male Mice and Human HCC Cells
Previous work has demonstrated androgen receptor (AR)
as a key regulator of HCC development through bothDecember 9, 2013 ª2013 Elsevier Inc. 729
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Figure 4. Regulation of Il-6 Expression in Ncoa5+/– Male Mice Compared to WT Male Mice
(A) The bar graph showing serum IL-6 concentration inWT andNcoa5+/male mice (n = 3) with the indicated ages. Values are mean ± SEM; N.S., no significance.
(B) Quantitative RT-PCR (qRT-PCR) of Il-6 mRNA levels in WT and Ncoa5+/ mouse livers with the indicated ages (n = 4). Values are mean ± SEM; *p% 0.05;
**p% 0.01.
(C) Representative IHC stained sections of IL-6 in livers from 6-month-old WT and Ncoa5+/ male mice.
(D) Quantification of the numbers of IL-6 positive cells per high-power field (HPF) (n = 3). Five HPFs per section were counted. Values are mean ± SEM; *p% 0.05.
(E) Representative dual IF staining of IL-6 (red) and MAC-2 (green) in livers from 10-month-old WT and Ncoa5+/male mice. Nuclei (blue) were stained with DAPI.
(F) Quantification of the numbers of IL-6/MAC2-positive cells per HPF (n = 3). Five HPFs per section were counted. Values are mean ± SEM; *p% 0.05.
(G) Western blot analysis of lysates from 10-month-old WT and Ncoa5+/ male and female liver tissues, liver tumors, and adjacent liver tissues from Ncoa5+/
male mice with antibodies against phospho-STAT3 (Tyr 705) and total STAT3. b-actin serves as loading control.
(legend continued on next page)
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AC
E
H I
F G
D
B Figure 5. Effects of NCOA5 Deficiency on
AR Expression in Mouse Livers and
Cultured Human HCC Cell Lines
(A) Western blot analysis of AR protein levels in the
cell extracts from HepG2 cell lines after treated
with 0, 1 ng/mL, and 10 ng/mL IL-6, respectively.
b-actin serves as loading control.
(B) qRT-PCR analysis of Ar mRNA levels in WT
versus Ncoa5+/ livers derived from 5-month-old
male mice (n = 4). Values are mean ± SEM;
*p% 0.05.
(C) AR protein levels in WT versus Ncoa5+/ liver
tissue lysates derived from 10-month-old male
mice. Results were quantified and normalized to
b-actin.
(D)Western blot analysis of AR and TGF-b1 protein
levels in three pairs of liver tumors versus their
adjacent nontumorous tissues. The ratios of AR/
b-actin are listed.
(E–G) Knockdown of NCOA5 results in increased
AR mRNA levels in human HCC PLC/PRF/5 cells.
Whole-cell lysates were made from pooled cells
expressing a scramble shRNA-Con, NCOA5-SH1,
and NCOA5-SH5 that specifically target NCOA5
and then subjected to western blotting with anti-
bodies against NCOA5 and b-actin (E). The bar
graphs show quantitative RT-PCR analysis of AR
(F) and IL-6 (G) mRNA levels in indicated cells.
Experiments were repeated two times. Data
represent mean ± SD of triplicates from a repre-
sentative experiment (*p% 0.05).
(H) qRT-PCR of FasnmRNA levels in 10-month-old
WT andNcoa5+/male mouse livers (n = 4). Values
are mean ± SEM; *p% 0.05.
(I) A representative IHC-stained section of FAS
in livers from 10-month-oldWT andNcoa5+/male
mice.
See also Figure S5.
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Decreased NCOA5 Causes Glucose Intolerance and HCCandrogen-dependent and androgen-independent pathways
(Kalra et al., 2008; Ma et al., 2008; Nagasue et al., 1992). Since
IL-6 is able to increase AR expression in prostate cancer cells
(Lin et al., 2001), we wondered whether NCOA5 deficiency
increased AR expression in the liver. Initially, we observed that
recombinant IL-6 was able to increase AR expression in HCC
HepG2 cells in vitro (Figure 5A). Next, we found that levels of
Ar mRNA and protein were significantly increased in Ncoa5+/
livers compared to livers of Ncoa5+/+ littermates (Figures 5B
and 5C). Moreover, the protein levels of AR and an AR down-
stream target, TGF-b1, were significantly elevated in HCCs
arising inNcoa5+/mice compared with their adjacent nontumo-
rous liver tissues (Figure 5D). Interestingly, knockdown of(H) qRT-PCR of Socs3 mRNA of 10-month-old WT and Ncoa5+/ male mouse liv
(I) qChIP assay for NCOA5 and ERa binding on Il-6 promoter in cultured mouse RA
and coactivator CBP were used to precipitate DNA-protein complexes. qRT-PC
recruitment of indicated proteins on the Il-6 promoter. Fold enrichment of qChIP
times. Values are mean ± SEM; **p% 0.01.
(J) The bar graph shows relative luciferase activity of the Il-6 promoter in RAW
transfected p65 before and after LPS treatment. Experiments were repeated thr
(K) qChIP analysis of RNA Pol II assembly on the Il-6 promoter in livers of 6-mon
serine 2 of C-terminal domain, and ERa were used to precipitate DNA-protein
expressed in fold enrichment of ChIP sample over input sample. A representative
See also Figure S4.
CaNCOA5 without IL-6 treatment also increased the mRNA level
of AR, but not the level of IL-6 mRNA, in cultured human HCC
PLC/PRF/5 cells (Figures 5E–5G). These results indicate that
elevated AR expression in Ncoa5+/ livers might be due to
both intrinsic effects of NCOA5 deficiency and extrinsic effects
of Kupffer cell-derived IL-6 on hepatocytes. In addition, by using
mouse signal transduction pathway PCR array, we identified
multiple genes in the NF-kB, androgen, and insulin pathways
whose expressionmight be altered inNcoa5+/ livers (Figure S5).
Notably, fatty acid synthase (Fas/Fasn) mRNA was about 6-fold
higher in Ncoa5+/ male mouse livers than in Ncoa5+/+ control
mice (Figure 5H). IHC staining for FAS protein confirmed that
FAS expression was increased in Ncoa5+/ male mouse liversers (n = 3). Values are mean ± SEM; **p% 0.01.
W 264.7 cells in the absence and presence of E2. Antibodies for NCOA5, ERa,
R analysis of precipitated Il-6 promoter DNA was performed to quantify the
sample relative to input sample is shown. Experiments were repeated three
264.7 cells transfected with control or NCOA5 plasmids without or with the
ee times. Values are mean ± SEM; *p% 0.05; **p% 0.01.
th-old WT and Ncoa5+/ male mice. Antibodies for RNA Pol II, phospho-Pol II
complex. The levels of protein-bound DNA were measured by qRT-PCR and
of two independent experiments is shown. Values are mean ± SD; **p% 0.01.
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Figure 6. Effects of Heterozygous Deletion
of Il-6 on the Onset of Glucose Intolerance
and HCC Development in Ncoa5+/– Male
Mice
(A) qRT-PCR analysis of Il-6 mRNA levels in livers
from 8-week-old Ncoa5+/Il-6+/+ and Ncoa5+/
Il-6+/ male mice (n = 3). Values are mean ± SEM;
*p% 0.05.
(B) Blood glucose levels of 12-hr-fasted 6-week-
old Ncoa5+/Il-6+/+, Ncoa5+/Il-6+/ and Ncoa5+/+
Il-6+/+ male mice (n = 3–5). Values are mean ±
SEM; **p% 0.01.
(C) GTT of 6-week-old Ncoa5+/Il-6+/+, Ncoa5+/
Il-6+/ and Ncoa5+/+Il-6+/+ male mice (n = 3–5).
Values are mean ± SEM; *p % 0.05; **p % 0.01
Ncoa5+/Il-6+/ versus Ncoa5+/Il-6+/+.
(D) ITT of 8-week-old Ncoa5+/Il-6+/+, Ncoa5+/
Il-6+/, and Ncoa5+/+Il-6+/+ male mice (n = 3–5).
Values are mean ± SEM; **p % 0.01 Ncoa5+/
Il-6+/ versus Ncoa5+/Il-6+/+.
(E) Representative macroscopic appearance of
livers derived from 18-month-old Ncoa5+/Il-6+/+
and Ncoa5+/Il-6+/ male mice (n = 5 per group).
Dash circle lines and arrows indicate tumors.
(F andG) The bar graphs show the numbers (F) and
the maximal volume (G) of liver tumors arising in
18-month-old Ncoa5+/Il-6+/+ and Ncoa5+/Il-6+/
male mice (n = 5 per group). Values are mean ±
SEM; *p% 0.05.
(H) Western blot analysis of pSTAT3 (Tyr 705),
STAT3, and IL-6 levels in four pairs of liver tumors
(T) and their adjacent nontumorous liver tissues (A)
in 18-month-old Ncoa5+/Il-6+/+ and Ncoa5+/
Il-6+/ male mice. b-actin serves as a loading
control.
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Decreased NCOA5 Causes Glucose Intolerance and HCCrelative to wild-type control livers (Figure 5I). FAS was previously
found to contribute to hepatocarcinogenesis and hepatic insulin
resistance (Kalra et al., 2008; Kubota et al., 2000; Ma et al., 2008;
Menendez et al., 2009; Nagasue et al., 1992; Postic and Girard,
2008). Thus, other factors such as increased expression of AR,
TNF-a, and FAS might also contribute to the development of
T2D and HCC in Ncoa5+/ male mice.
Heterozygous Deletion of Il-6 Prevents Glucose
Intolerance and Partially Deters HCC Development in
Ncoa5+/– Male Mice
To determine whether increased IL-6 expression is responsible
for the phenotypes observed in Ncoa5+/ mice, we generated
mice bearing dual heterozygous deletions of Il-6 and Ncoa5
genes by crossing Ncoa5+/ mice with Il-6/ (B6.129S6-IL-
6tm1Kopf) mice. The level of Il-6 mRNA in livers of Ncoa5+/
Il-6+/ males was decreased by 50% compared to livers of
Ncoa5+/Il-6+/+ male littermates (Figure 6A). Notably, heterozy-732 Cancer Cell 24, 725–737, December 9, 2013 ª2013 Elsevier Inc.gous Il-6 deletion in Ncoa5+/ male mice
profoundly improved their fertility, as dou-
ble Ncoa5+/Il-6+/ male mice became
fertile. However, no Ncoa5/ Il-6+/
pup was generated (S.G., F.C., G. Perez,
and H.X., unpublished data). We found
that Ncoa5+/Il-6+/ male mice exhibited
a significant improvement in fasting blood glucose levels,
GTTs, and ITTs compared with their Ncoa5+/Il-6+/+ male litter-
mates at the age of 6 weeks (Figures 6B–6D). Improved fasting
blood glucose levels and GTTs were also observed in
Ncoa5+/Il-6+/ Balb/c mice (Figures S2B and S2C). Moreover,
heterozygous Il-6 deletion did not block tumor initiation, as
HCC was observed in four out of five (80%) Ncoa5+/Il-6+/
male mice by the age of 18 months. However, the number of
tumors per mouse and the tumor volumes are significantly
reduced compared to tumors arising in Ncoa5+/Il-6+/+ male
mice (Figures 6E–6G). Western blot analysis revealed that the
levels of pSTAT3 and total STAT3 as well as IL-6 levels were
reduced in tumors and their nontumorous liver tissues in
Ncoa5+/Il-6+/ male mice compared with those in Ncoa5+/
Il-6+/+ male mice (Figure 6H). Together, these results suggest
that Ncoa5 deficiency-induced glucose intolerance and HCC
development in male mice are dependent, at least in part, on
increased IL-6 expression in livers.
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Figure 7. Expression of NCOA5 and
SNCOA5 in Human HCC Specimens
(A) Representative sequence traces showing
NCOA5 and SNCOA5 cDNA sequences amplified
from five pooled normal human liver tissues or
human HCC tumor specimens (n = 9) as indicated.
Diagrams show exons of NCOA5 and SNCOA5 as
indicated.
(B and C) qRT-PCR showing NCOA5 (B) or
SNCOA5 (C) mRNA levels in pairs of human HCC
and adjacent noncancerous tissues (n = 30) versus
normal human liver tissues (N1–N3) as indicated.
Red dotted line indicates at least 50% reduction of
NCOA5 mRNA levels compared to normal human
livers. Primers specific for NCOA5 or SNCOA5
mRNAwere used to perform qRT-PCR. Patients 6,
10, 19, and 30 have T2D and are marked with an
asterisk (*). Values are mean ± SD; *p % 0.05;
**p% 0.01.
See also Figure S6.
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Decreased NCOA5 Causes Glucose Intolerance and HCCDecreased Expression of NCOA5 and Overexpression of
the Alternatively Spliced Form of NCOA5 Are Frequently
Associated with Human HCC
To extend our findings to human HCC, we sequenced NCOA5
cDNAs amplified from nine pairs of HCC and adjacent non-
cancerous tissue samples frommale patients as well as a pooled
mRNA sample from five normal male human livers. We identified
an alternatively spliced form of NCOA5 mRNA in all of the
samples, which encodes a shortened NCOA5 (SNCOA5). It
contains 406 amino acids due to a frame-shifting insertion
caused by an extended exon 7, containing the first 23 nucleo-
tides of intron 7 (Figure 7A). SNCOA5 is unlikely to have a
transcriptional activation function as it lacks the transcriptional
activation domain at the carboxyl terminus of NCOA5 and fails
to enhance ERa-mediated transcriptional activation in luciferase
reporter assays (Figures S6A–S6D). Next, we examined theCancer Cell 24, 725–737,mRNA levels of NCOA5 and SNCOA5
in 30 pairs of frozen HCC and adjacent
noncancerous tissue specimens (four
pairs are from diabetic patients) with
quantitative RT-PCR analysis. We de-
tected a statistically significant reduction
in NCOA5 expression in 40% (12/30) of
HCC specimens when comparing
NCOA5 mRNA levels in HCC versus
adjacent noncancerous liver (Figure 7B).
In contrast, SNCOA5 expression was
significantly increased in 43% (13/30)
of HCC specimens compared with their
adjacent noncancerous tissues (Fig-
ure 7C). Western blot analysis confirmed
that the protein level of SNCOA5 was
significantly increased in two of four
tested HCC specimens (Figure S6E).
This inverse correlation between low
NCOA5 expression and high SNCOA5
expression in human HCC specimens
indicates that NCOA5 deficiency maycontribute to human HCC development. It is noteworthy that
at least 63% (19/30) of HCC specimens showed over 50%
reduction in the NCOA5 mRNA level in adjacent noncancerous
tissues when compared to normal human liver tissue controls
(Figure 7B); among them, three of four specimens from diabetic
patients showed remarkable reduction in the NCOA5 mRNA
level. In addition, we have examined the microarray data of
pancreatic islets from seven normal and five T2D patients
reported by Kahn and colleagues (Gunton et al., 2005), which
is available at the website of the Diabetes Genome Anatomy
Project (http://www.diabetesgenome.org). We identified that
two out of five patients with T2D displayed a 70%–80% reduc-
tion of NCOA5 expression in pancreatic islets relative to normal
control subjects (data not shown). Taken together, our results
imply a potential association of reduced NCOA5 expression
with human T2D.December 9, 2013 ª2013 Elsevier Inc. 733
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Here, we describe that NCOA5 plays a critical role in suppressing
the development of glucose intolerance, a prediabetic status,
and HCC in mice, in part by regulating IL-6 expression in a
male-gender-specific fashion. Moreover, we show that reduced
NCOA5 expression is associated with a significant portion of
human specimens of HCCs and HCCs with concomitant T2D.
Taken together, our results suggest that NCOA5 deficiency is a
risk factor for bothHCC and T2D, which triggers a common path-
ogenic mechanism in the promotion of both diseases.
Previous studies have demonstrated that IL-6 and TNF-a in
Kupffer cells play key roles in HCC development in mice that
are induced by a chemical carcinogen (DEN) in dietary or genetic
obesity (Naugler et al., 2007; Park et al., 2010). It has been
proposed that the protective effect of estrogens on HCC is due
to the inhibition of IL-6 expression in Kupffer cells by estrogen-
bound ERa that assembles on the Il-6 promoter through inter-
action with NF-kB (Libermann and Baltimore, 1990; Naugler
et al., 2007; Ray et al., 1994; Stein and Yang, 1995). However,
themolecular mechanisms underlying increased IL-6 expression
in HCC remain largely unidentified. Our results suggest that
NCOA5 is a critical regulator in controlling IL-6 expression and
HCC development in mice, which is consistent with previous
models of hepatocarcinogenesis (Farazi and DePinho, 2006;
Feng, 2012; Naugler et al., 2007). Although increased IL-6
expression was detected predominantly in Kupffer cells in
Ncoa5+/ male livers, our results do not exclude the possibility
that NCOA5 haploinsufficiency also increases autocrine IL-6
production by hepatocellular carcinoma progenitor cells
described recently (He et al., 2013). Importantly, reduced
NCOA5 expression and increased SNCOA5 were found
frequently in the cancerous tissues of human HCC specimens
compared to their adjacent noncancerous tissues, indicating
that partial loss of NCOA5 function may contribute to human
HCC development. The SNCOA5 apparently lacks the coactiva-
tion domain of NCOA5 and evidently failed to enhance
ERa-mediated transcription in response to estrogen in a lucif-
erase reporter assay, suggesting that SNCOA5 is a good candi-
date to be examined for its possible promoting role in human
HCC development. Thus, our results not only support the previ-
ous findings that Kupffer-cell-derived IL-6 contributes to the
gender disparity of HCC (Naugler et al., 2007), but also point
out the mechanism of IL-6 regulation by NCOA5 and its role in
the suppression of HCC development.
Our results suggest a critical role of increased hepatic IL-6-
STAT3 signaling in hepatocarcinogenesis, which is consistent
with previous reports that deletion of Il-6 reduced incidence of
tumors larger than 0.5 mm in diameter in mice treated with
DEN (Naugler et al., 2007) and that hepatocyte-specific
STAT3-deficient mice treated with DEN developed fewer and
smaller HCCs compared to wild-type mice (He et al., 2010).
Our results, nevertheless, do not suggest that increased IL-6
expression is the only mediator promoting hepatocarcinogene-
sis in Ncoa5+/ male mice. In fact, the correction of increased
IL-6 expression in Ncoa5+/ male mice with deletion of one Il-6
allele reduces, but not completely blocks, HCC growth. In addi-
tion, we observed that two of three Ncoa5+/Il-6/ male mice
did develop three small HCCs (%108 mm3) each at the age of734 Cancer Cell 24, 725–737, December 9, 2013 ª2013 Elsevier Inc.18 months, indicating that deletion of both Il-6 alleles does not
completely block HCC development in Ncoa5+/ male mice
(data not shown). Therefore, our results suggest that other
downstream targets of NCOA5 may also contribute to hepato-
carcinogenesis. Supporting this idea, we found that NCOA5
haploinsufficiency resulted in aberrant expression of other
genes, including Tnfa, Fasn, and Ar, that were previously
reported to contribute to the development of T2D and HCC
(Kalra et al., 2008; Ma et al., 2008; Naugler et al., 2007; Pikarsky
et al., 2004; Postic and Girard, 2008). Since NCOA5 could
regulate ERa-targeted genes via a direct interaction with ERa
(Jiang et al., 2004), it is possible that NCOA5 may regulate other
ERa-targeting genes in Kupffer cells as well as in hepatocytes.
Alternatively, NCOA5 may regulate genes independent of ERa
in glucose homeostasis and HCC development, as our current
evidence does not prove that the action of NCOA5 is dependent
on ERa. Indeed, NCOA5 is able to form a complex with SAM68,
hnRNP-G, and the transcription factors ZAP3, ILF2, and ILF3
(Ulke-Leme´e et al., 2007), and it may also regulate transcription
of genes targeted by other transcription factors such as ILF2 and
ILF3, which also warrants further exploration. Therefore, we
envision NCOA5 as a transcriptional coregulator that concomi-
tantly controls the expression of a set of genes in Kupffer cells
and/or hepatocytes that play key roles in hepatic inflammation,
apoptosis, and proliferation to influence the development of
HCC. Thus, it will be interesting for future studies to determine
whether NCOA5 deficiency-induced HCC is dependent on
ERa. Studies using mice bearing a cell-specific knockout of
Ncoa5 and/or compound knockout of its downstream targets
will help to clarify the mechanism of NCOA5 deficiency-induced
HCC and provide more mechanistic insights into HCC
development.
Our study also indicates that NCOA5 haploinsufficiency
causes glucose intolerance, a pathophysiological feature of
T2D in mice, through increased hepatic IL-6-STAT3 signaling.
There is current evidence supporting both beneficial and
detrimental effects of IL-6-STAT3 signaling on insulin sensitivity
in animals and humans, thus leading to a debate regarding the
role of IL-6 in insulin resistance and T2D. Evidently, IL-6
knockout mice display insulin resistance (Matthews et al.,
2010), suggesting an essential role for IL-6 in insulin sensitivity.
Conversely, genetically engineered mice with activation of
NF-kB in the liver had elevated serum levels of IL-6 and TNF-a
and displayed insulin resistance (Naugler and Karin, 2008).
Moreover, although the IL-6-STAT3 signaling in the liver can
promote insulin resistance by inhibiting insulin signaling through
SOCS3, this signaling is also critical for suppressing hepatic
glucose production through the regulation of insulin action in
the brain (Inoue et al., 2006). Thus, hepatic activation of IL-6-
STAT3 signaling may act to promote or ameliorate insulin
resistance. Our data here, however, suggest that persistently
increased IL-6 in the liver is necessary for the glucose intolerance
observed in Ncoa5+/male mice, as Ncoa5+/Il-6+/mice show
a significant improvement in insulin sensitivity. Notably, neither
the serum IL-6 level nor the serum insulin level was significantly
elevated in Ncoa5+/ male mice, indicating that NCOA5
deficiency does not cause a systemic elevation of IL-6 expres-
sion and sufficient compensatory insulin production. Presum-
ably, in the absence of compensatory serum insulin, activation
Cancer Cell
Decreased NCOA5 Causes Glucose Intolerance and HCCof IL-6-STAT3 signaling in the liver is unable to suppress hepatic
glucose production inNcoa5+/malemice through insulin action
in the brain. This may explain the development of hepatic insulin
resistance and glucose intolerance in Ncoa5+/male mice in the
presence of activated hepatic IL-6-STAT3 signaling. Thus, we
suggest that NCOA5 deficiency mainly inhibits hepatic insulin
signaling through elevated IL-6 in the liver, while accompanied
with the inhibition of compensatory insulin production by pancre-
atic b cells, leading to impaired glucose homeostasis. Clearly,
further studies will be a priority, including experiments to mea-
sure hepatic pancreatic b cell function and hyperinsulinemic-
euglycemic clamp assays to assess hepatic glucose production
and insulin sensitivity in adipocytes andmuscles inNcoa5+/ and
wild-type mice.
The early onset of glucose intolerance in Ncoa5+/ male mice
raises a question of whether the NCOA5 gene is a T2D sus-
ceptibility gene in humans. Noteworthy, the chromosomal region
20q13.1, where the NCOA5 gene locates, has long been known
to contain T2D susceptibility genes (Bento et al., 2008). Recently,
analysis of candidate genes in this region in two European Amer-
ican case-control populations revealed that NCOA5, along with
two other nearby genes, was associated with T2D (Bento
et al., 2008; Lewis et al., 2010). In addition, we have identified
that two out of five patients with T2D displayed a 70%–80%
reduction of NCOA5 expression in pancreatic islets relative to
normal controls (Gunton et al., 2005). Intriguingly, despite the
statistical insignificance, three of four human HCC specimens
with T2D analyzed in this study had a much lower NCOA5
expression in the adjacent nontumorous tissues compared to
the normal liver tissues. Taken together, this implies a potential
association of NCOA5 deficiency with human T2D. Thus, it will
be important for further studies to determine whether genetic
mutations and/or reduced expression of NCOA5 in liver and
pancreas correlate with patients with T2D or with both T2D
and HCC.
In summary, our work uncovers NCOA5 deficiency as a
common risk factor in glucose intolerance and HCC and raises
many questions about the upstream regulatory genes and down-
stream targets of NCOA5 in hepatocytes and Kupffer cells that
contribute to the pathogenesis of glucose intolerance and
HCC. Thus, our findings have tremendous potential impact on
the understanding of disease etiology and development of ther-
apeutic strategies for both T2D and HCCEXPERIMENTAL PROCEDURES
Generation of Ncoa5+/– and Ncoa5+/–Il-6+/– Mice
Details regarding the construction of a Ncoa5 targeting vector and the gener-
ation of aNcoa5 knockoutmouse on amixed 1293C57BL/6 or Balb/c genetic
background are provided in Supplemental Experimental Procedures. All mice
were and housed in microisolator cages at Michigan State University animal
facility. B6.129S6-Il-6tm1Kopf mice of C57BL/6 or Balb/c were purchased
from Jackson Laboratory. To generate Ncoa5+/Il-6+/ mice, Il-6/ C57BL/
6 or Balb/c male mice were mated with Ncoa5+/ female mice of mixed
129 3 C57BL/6 or Balb/c genetic background to obtain an F1 generation
Ncoa5+/ Il-6+/, respectively. Ncoa5+/ Il-6+/ F1 male and female mice
were subsequently mated to derive Ncoa5+/ Il-6+/ and Ncoa5+/ Il-6+/+
mice of mixed 1293 C57BL/6 or Balb/c genetic background. All experimental
procedures on mice were approved by the Michigan State University Institu-
tional Animal Care and Use Committee and conducted in accordance with
institutional and national guidelines.CaHuman Tissue Samples
Total mRNAs from a pooled sample of five normal male human autopsy liver
tissues (N1) and a pair of HCC and adjacent tissues from a male patient
were purchased from Biochain. Twenty-nine pairs of frozen human HCC and
noncancerous adjacent liver tissues from patients (25 males and 4 females)
with HCC and two frozen human liver tissues (N2 and N3) from female patients
with hepatic hemangioma or gallstones were collected from consenting
patients after hepatectomy in Nanfang Hospital, Southern Medical University,
China. The age range was 39–76 years. The experimental procedures were
approved by the Research Ethics Committee of Southern Medical University
and the Biomedical and Health Institutional Review Board of Michigan State
University.
Statistical Analysis
The differences between groups were analyzed using a Student’s two-tailed
t test. Survival curves were compared using a log-rank (Mantel-Cox) test.
Tumor incidences were compared using a c2 test. Values are expressed as
mean ± SEM or SD; p% 0.05 is considered statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccr.2013.11.005.
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